1-tert-butoxydodecane | 61548-83-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-tert-butoxydodecane
• 英文别名: 1-tert-butoxy-dodecane；Dodecyl-t-butyl-ether；Dodecyl-t-butylaether；tert-Butyl n-dodecyl ether；1-[(2-methylpropan-2-yl)oxy]dodecane
• CAS: 61548-83-2
• 化学式: C₁₆H₃₄O
• 分子量: 242.445
• InChiKey: ZPGDKUJNUNOUME-UHFFFAOYSA-N

物化性质

• 沸点：
  158 °C(Press: 15 Torr)
• 密度：
  0.810±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  17
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

反应信息

• 作为产物：
  描述：

  十二烷醇 、 异丁烯 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以76%的产率得到1-tert-butoxydodecane
  参考文献：
  名称：

  A new and specific method for the protection of phenols as the corresponding tert-butyl ethers

  摘要：

  DOI：

  10.1021/jo00351a028

文献信息

• Amine Cationic Lipids and Uses Thereof
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US20140371293A1

  公开（公告）日：2014-12-18

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。具体而言，这些化合物包括一类具有胺基团的阳离子脂质，例如氨基-胺或氨基-酰胺基团。这些脂质化合物可用于体内或体外传递一个或多个药物（例如，多聚阴离子荷载物或反义荷载物，如RNAi药物）。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• Multicomponent diesel composition
  申请人：Neste Oyj

  公开号：US11319500B2

  公开（公告）日：2022-05-03

  The invention discloses novel diesel fuel compositions including a renewable diesel component, a fossil diesel component and an oxygenate component, as well as methods for manufacture and use of a combination of a renewable diesel component, and an oxygenate component for reducing particulate matter emissions.

  本发明公开了新型柴油组合物，包括可再生柴油组分、化石柴油组分和含氧组分，以及生产和使用可再生柴油组分和含氧组分组合物以减少颗粒物排放的方法。
• Process for formulating an anionic agent
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US11351265B2

  公开（公告）日：2022-06-07

  Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.

  包含阴离子剂（如含脂微粒中的核酸）的制剂 配制包含阴离子剂（如核酸）的含脂微粒的方法、制备包含阴离子剂（如核酸）的含脂微粒的方法、向有需要的患者治疗递送阴离子剂的方法，其中阴离子剂被配制在本文所述的含脂微粒中。